Clinical Evaluation of Brahmi in Cognitive Decline

Abstract

Brahmi (Bacopa monnieri) is the cornerstone Medhya Rasayana herb in the classical Ayurvedic cognitive repertoire, used for centuries for memory support, attention enhancement, and broadly the clinical territory modern medicine labels cognitive decline. Modern clinical evaluation of Brahmi has matured substantially over the past two decades, with standardised extracts, controlled trials across multiple cognitive populations, and a growing systematic review literature. Brahmi now sits alongside Ginkgo biloba as one of the most extensively clinically characterised botanical cognitive interventions, and it increasingly deserves to be taken seriously in European integrative neurology and integrative-memory clinics. This review covers 54 primary clinical studies published between 2005 and 2021 evaluating Brahmi in cognitive-relevant indications, grouped under five clinical evaluation frames: B1 (healthy adults and cognitive enhancement), B2 (mild cognitive impairment), B3 (age-related cognitive decline without formal MCI diagnosis), B4 (neurodegenerative disease including Alzheimer's-type dementia and Parkinson's disease cognitive impairment), and B5 (integrated multi-herb Medhya Rasayana protocols). Each frame is scored with the Brahmi Cognitive Performance Index (BCPI). Mild cognitive impairment (B2) produced the strongest clinical signal at BCPI 0.844, followed by age-related cognitive decline (B3) at 0.828 and healthy-adult cognitive enhancement (B1) at 0.806. Neurodegenerative disease (B4) scored lowest at 0.652, with the evidence supporting adjunctive rather than primary therapeutic use in this population